IDH1 and acute myeloid leukemia: For instance, the development and clinical utility of IDH1/2 inhibitors for IDH1/2 mutant AML22–25 as wells as BCL-2 inhibitors26 illustrates that untangling metabolic changes could provide therapeutic avenues in AML.